Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

PURPOSE: Tepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure, and efficacy and safety outcomes. METHODS: Exposure–efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wenyuan, Hietala, Sofia Friberg, Nyberg, Joakim, Papasouliotis, Orestis, Johne, Andreas, Berghoff, Karin, Goteti, Kosalaram, Dong, Jennifer, Girard, Pascal, Venkatakrishnan, Karthik, Strotmann, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300558/
https://www.ncbi.nlm.nih.gov/pubmed/35771259
http://dx.doi.org/10.1007/s00280-022-04441-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300558/
https://www.ncbi.nlm.nih.gov/pubmed/35771259
http://dx.doi.org/10.1007/s00280-022-04441-3

Ejemplares similares